From Cell Bank To Clinic Faster: GMP Manufacturing & Characterization

Bringing a biologic to the clinic demands both speed and uncompromising quality. Traditional cell bank release strategies often rely on lengthy, sequential workflows and time-intensive assays that can extend development timelines to six months or longer. Today, validated molecular technologies are transforming this process.

PCR-based mycoplasma testing, next-generation sequencing for adventitious agent detection, and rapid microbial methods replace slower, conventional assays, delivering reliable results in days rather than weeks. When combined with risk-based approaches and concurrent workflows, such as performing pre-bank testing alongside clone selection, these innovations can shorten timelines by up to 10 weeks while maintaining compliance with global regulatory expectations.

An integrated, single-site model further streamlines development by combining GMP cell banking, characterization, and advanced analytical testing in one location. This reduces operational complexity, minimizes delays, and improves coordination across critical activities, enabling a faster, more efficient path from cell bank to clinic with confidence in the quality, safety, and integrity of every step.